These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 29682796)

  • 1. Phase 2a, randomized, double-blind, placebo-controlled, multicentre, parallel-group study of an H
    Kollmeier AP; Greenspan A; Xu XL; Silkoff PE; Barnathan ES; Loza MJ; Jiang J; Zhou B; Chen B; Thurmond RL
    Clin Exp Allergy; 2018 Aug; 48(8):957-969. PubMed ID: 29682796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2a study of toreforant, a histamine H
    Kollmeier AP; Barnathan ES; O'Brien C; Chen B; Xia YK; Zhou B; Loza MJ; Silkoff PE; Ge M; Thurmond RL
    Ann Allergy Asthma Immunol; 2018 Nov; 121(5):568-574. PubMed ID: 30102965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis.
    Murata Y; Song M; Kikuchi H; Hisamichi K; Xu XL; Greenspan A; Kato M; Chiou CF; Kato T; Guzzo C; Thurmond RL; Ohtsuki M; Furue M
    J Dermatol; 2015 Feb; 42(2):129-39. PubMed ID: 25491792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
    Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
    Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
    Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
    Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.
    Hanania NA; Korenblat P; Chapman KR; Bateman ED; Kopecky P; Paggiaro P; Yokoyama A; Olsson J; Gray S; Holweg CT; Eisner M; Asare C; Fischer SK; Peng K; Putnam WS; Matthews JG
    Lancet Respir Med; 2016 Oct; 4(10):781-796. PubMed ID: 27616196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial.
    Grekowitz E; Metz M; Altrichter S; Bauer A; Brockow K; Heine G; Lionnet L; Saday KK; Hultsch T; Søerensen OE; Maurer M
    Br J Dermatol; 2024 May; 190(6):825-835. PubMed ID: 38308655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
    Harrison TW; Chanez P; Menzella F; Canonica GW; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; McDermott L; Garcia Gil E; Zangrilli JG;
    Lancet Respir Med; 2021 Mar; 9(3):260-274. PubMed ID: 33357499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group.
    Liu MC; Dubé LM; Lancaster J
    J Allergy Clin Immunol; 1996 Nov; 98(5 Pt 1):859-71. PubMed ID: 8939149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 2a Study of DP
    Asano K; Sagara H; Ichinose M; Hirata M; Nakajima A; Ortega H; Tohda Y
    J Allergy Clin Immunol Pract; 2020 Apr; 8(4):1275-1283.e1. PubMed ID: 31778823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild-to-moderate asthma.
    Ortega H; Fitzgerald M; Raghupathi K; Tompkins CA; Shen J; Dittrich K; Pattwell C; Singh D
    Clin Exp Allergy; 2020 Feb; 50(2):189-197. PubMed ID: 31659803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
    Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.
    Knorr B; Franchi LM; Bisgaard H; Vermeulen JH; LeSouef P; Santanello N; Michele TM; Reiss TF; Nguyen HH; Bratton DL
    Pediatrics; 2001 Sep; 108(3):E48. PubMed ID: 11533366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group.
    Reiss TF; Chervinsky P; Dockhorn RJ; Shingo S; Seidenberg B; Edwards TB
    Arch Intern Med; 1998 Jun; 158(11):1213-20. PubMed ID: 9625400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
    Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.
    Corren J; Weinstein S; Janka L; Zangrilli J; Garin M
    Chest; 2016 Oct; 150(4):799-810. PubMed ID: 27018175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma.
    Barnes N; Pavord I; Chuchalin A; Bell J; Hunter M; Lewis T; Parker D; Payton M; Collins LP; Pettipher R; Steiner J; Perkins CM
    Clin Exp Allergy; 2012 Jan; 42(1):38-48. PubMed ID: 21762224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group.
    Malmstrom K; Rodriguez-Gomez G; Guerra J; Villaran C; Piñeiro A; Wei LX; Seidenberg BC; Reiss TF
    Ann Intern Med; 1999 Mar; 130(6):487-95. PubMed ID: 10075616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.